SG3 Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

SG3 Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,000	Closed	-$351K	–	1413
2021 Q3	$351K	Hold	20,000	–	–	0.01%	674
2021 Q2	$194K	Sell	20,000 -30,000	-60%	-$282K	0.01%	833
2021 Q1	$537K	Buy	50,000 +30,000	+150%	+$371K	0.01%	759
2020 Q4	$294K	Buy	+20,000	New	+$288K	0.01%	814

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

SG3 Management's TRIL Position: Q1 2021 in Review

SG3 Management sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2021, closing a stake of 85,000 shares — an estimated $1.05M sold.

SG3 Management first reported a position in TRIL in Q4 2020 and held it in 1 quarter. The position peaked at $1.25M in Q4 2020. 125 funds tracked by Wall St. Rank hold TRIL as of Q1 2021.

SG3 Management reported no remaining Trillium Therapeutics Inc. position as of Q1 2021 after selling out during the quarter.
SG3 Management sold 85,000 Trillium Therapeutics Inc. shares in Q1 2021, an estimated $1.05M.
SG3 Management first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 1 quarter.
SG3 Management's Trillium Therapeutics Inc. position peaked at $1.25M in Q4 2020.
125 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2021.

Based on SG3 Management's 13F filing for Q1 2021, filed 17 May 2021.